TG Therapeutics Inc (TGTX)

[postmeridiem]

Regarding the SPA(s):

I heard the TGTX CEO (Mike Weiss) mention "the SPA" during the Oppenheimer conference 3/21/17. I emailed TGTX's IR Dept. to request clarification, and the VP of Investor Relations (Jenna A. Bosco) replied within an hour:

Thank you for the note, XXXXXXXX.

I just re-listened to the time point in question (13:50) and at that moment Mike
Weiss is referring to the SPA we currently have in place for our UNITY-CLL
trial, which is currently a 4 arm study evaluating:
1) the combination of TG-1101 plus TGR-1202 vs.
2) Gazyva Chlorambucil vs.
3) TG-1101 Single Agent vs.
4) TGR-1202 Single Agent

The GENUINE trial, evaluating TG-1101 plus ibrutinib versus ibrutinib alone, was
amended in October of 2016, and as so, the revised GENUINE trial was no longer
being conducted pursuant to an SPA.

Please let me know if you have any additional questions.

Best,
Jenna


Jenna A. Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
2 Gansevoort Street, 9th Floor
New York, NY 10014
Office: 212.554.4351
Fax: [phone]
Email: [e-mail]